Condition: Coronary Artery Calcification · Metabolic Syndrome · Dyslipidemias · Sponsor: Samsung Medical Center
The aim of this study is to compare safety and efficacy between the aggressive treatment with combination of high-intensity statin and ezetimibe and the current standard lipid lowering treatment in asymptomatic patients with presence of coronary calcification.
This description comes directly from the study's public registry record.
Seung-Hyuk Choi, MD · 82-2-3410-3419 · sh1214.choi@samsung.com
Ki Hong Choi, MD · 82-2-3410-6653 · cardiokh@gmail.com
Always discuss trial participation with your own doctor first.
| SamsungMedicalCenter | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05845424